INTRODUCTION

Routine prophylaxis with factor VIII (FVIII) is the current therapeutic approach for people with severe haemophilia A (PwHA), as it reduces the frequency of bleeding episodes, prevents joint damage and improves health-related quality of life (HRQoL). However, owing to the half-life of standard half-life (SHL) FVIII, PwHA must inject themselves frequently (on average three times per week) to maintain plasma trough FVIII levels ≥ 1%. This represents a substantial burden and offers limited options to tailor prophylaxis to an individual patient’s needs, which may impact adherence. Complete prevention (abolition) of joint bleeding, the key to successful long-term outcomes, is difficult using SHL FVIII products.

Altering the molecular structure of FVIII to modify its pharmacokinetics (PK) can overcome the main drawbacks of SHL FVIII products caused by their short half-life. In particular, the high frequency of injections may impact adherence which in turn impacts FVIII levels, with subsequent increased risk of breakthrough bleeds, especially in patients with more rapid clearance, very active lifestyle and/or pre-existing joint damage.

Recombinant FVIII Fc fusion protein (rFVIIIFc; Elocta®, Sobi; Eloctate®, Sanofi) is a recombinant fusion protein that undergoes slower clearance from the body than SHL FVIII products. This pharmacokinetic property of rFVIIIFc allows prophylactic administration every 3-5 days, or once weekly in selected patients, with doses adjusted to patient needs and clinical outcomes. Higher FVIII levels can be achieved maintaining dosing frequency similar to that usually applied with SHL FVIII. This review provides a summary of recent data from the A-LONG, Kids A-LONG, ASPiRE and PUPs A-LONG studies and recently published real-world experience relevant to rFVIIIFc use in individualised regimens. The review also introduces ongoing studies of rFVIIIFc, including its use for induction of immune tolerance, and discusses some aspects to consider when switching patients to rFVIIIFc and managing ongoing treatment. In summary, rFVIIIFc is suitable for individualised prophylaxis regimens that can be tailored according to patient clinical needs and lifestyle.

KEYWORDS
factor VIII, factor VIII-Fc fusion protein, haemophilia A, half-life, immune tolerance, prophylaxis, recombinant fusion proteins, rFVIIIFc, surgical haemostasis
Clinical trials

**Previously treated** NCT01027377 (Phase II/IIa; N = 16)
- Previously treated patients with severe haemophilia A
- ≥ 12 years of age
- Primary endpoint:
  - Safety
  - Inhibitor and antibody development

**Previously untreated patients** NCT02234323 (Phase III; N = 103)
- Previously untreated patients with severe haemophilia A
- ≤ 5 years of age
- Primary endpoint:
  - Inhibitor development

**A-LONG** NCT01181128 (Phase III; N = 165)
- Previously treated patients with severe haemophilia A
- ≥ 12 years of age
- Primary endpoints:
  - ABR
  - Inhibitor development
  - Adverse events

**ASPIRE** NCT01454739 (Phase III; N = 211)
- Extension study of A-LONG and Kids A-LONG
- Primary endpoint:
  - Inhibitor development

**ReITIrate** NCT03103542 (Phase IV; N = 16)
- Patients with severe haemophilia A with previous failed ITI attempts
- Primary endpoint:
  - ITI success

**verITI-8** NCT03093480 (Phase IV; N = 16)
- Patients with severe haemophilia A undergoing first ITI treatment
- Primary endpoint:
  - Time to tolerisation

**PREVENT** NCT03055611 (N = 198)
- Previously treated patients with haemophilia A or B receiving FVIII/Fc and rFIXFc, respectively
- Primary endpoints:
  - ABR
  - Annualised injection frequency
  - Annualised factor consumption

**A-SURE** NCT02976753 (N = 358)
- Previously treated patients with haemophilia A receiving rFVIIIFc vs conventional FVIII
- Primary endpoints:
  - ABR
  - Annualised injection frequency
  - Annualised factor consumption

**Factor utilisation and health outcomes** NCT02796222 (N ~120)
- Previously treated patients with severe or moderate haemophilia A or B
- Primary endpoint:
  - Annualised factor consumption over a 24-month period

**ATHN 2** NCT02546622 (N = 310)
- Previously treated patients with haemophilia A or B
- Primary endpoint:
  - Rate of inhibitor development at 1 year or 50 exposure days

**A-MORE** NCT04293523 (N ~300)
- Patients with haemophilia A (all severities)
- Primary endpoints:
  - Target joint development
  - Target joint resolution
  - Target joint recurrence
  - Annualised joint bleeding rate

**ITI chart review** NCT03951103 (N ~50)
- Patients with haemophilia A treated with rFVIIIFc for ITI
- Primary endpoints include:
  - Dose, injection frequency and duration of ITI
  - Overall outcome of ITI

**Musculoskeletal health** NCT03914209 (N ~40)
- Patients with haemophilia A
- Primary endpoint:
  - Bleeding frequency at 1 year

**Completed**

**Completed non-interventional real-world Phase IV post-marketing studies**

**PREVENT** NCT03055611 (N = 198)
- Previously treated patients with haemophilia A or B receiving FVIII/Fc and rFIXFc, respectively
- Primary endpoints:
  - ABR
  - Inhibitor development
  - Adverse events

**Kids A-LONG** NCT01458106 (Phase III; N = 71)
- Previously treated patients with severe haemophilia A
- < 12 years of age
- Primary endpoint:
  - Inhibitor development

**Ongoing**

**Ongoing non-interventional real-world Phase IV post-marketing studies**

**ATHN 2** NCT02546622 (N = 310)
- Previously treated patients with haemophilia A or B
- Primary endpoint:
  - Rate of inhibitor development at 1 year or 50 exposure days

**A-MORE** NCT04293523 (N ~300)
- Patients with haemophilia A (all severities)
- Primary endpoints:
  - Target joint development
  - Target joint resolution
  - Target joint recurrence
  - Annualised joint bleeding rate

**Factor utilisation and health outcomes** NCT02796222 (N ~120)
- Previously treated patients with severe or moderate haemophilia A or B
- Primary endpoint:
  - Annualised factor consumption over a 24-month period

**Musculoskeletal health** NCT03914209 (N ~40)
- Patients with haemophilia A
- Primary endpoint:
  - Bleeding frequency at 1 year

**FIGURE 1** Overview of key interventional clinical trials and prospective, non-interventional, real-world studies. Abbreviations: ABR, annualised bleeding rate; ITI, immune tolerance induction; N, study sample size (according to clinicaltrials.gov); FVIII, factor VIII; rFIXFc, recombinant factor IX Fc; rFVIIIFc, recombinant factor VIII Fc [Colour figure can be viewed at wileyonlinelibrary.com]
and is approved for the prophylaxis and treatment of bleeding in PwHA of all age groups. For long-term prophylaxis, the recommended dose of rFVIIIFc is 50 IU/kg every 3-5 days, with the dose adjusted in the range of 25-65 IU/kg based on the patient’s response and/or needs, although higher dose or frequency may be required in paediatric patients.

This review covers three main topics on rFVIIIFc for PwHA: structural and PK properties of rFVIIIFc; published and ongoing trials and real-world experience outside clinical trials (Figure 1); and the potential benefits of rFVIIIFc therapy and considerations for treatment.

2 | PHARMACOLOGICAL PROFILE OF RFVIIIFC

2.1 | Fusion protein characteristics

rFVIIIFc is a recombinant fusion protein comprising a single molecule of B-domain-deleted rFVIII covalently fused to the Fc domain of human immunoglobulin (lg) G1 without a linker sequence (Figure 2). rFVIIIFc, as a single protein, is produced in a human cell line (human embryonic kidney cells, HEK293) using recombinant DNA technology. rFVIIIFc manufacture does not use any animal-derived components and involves multistep purification with a novel affinity chromatography adsorbent and 15 nm pore size virus removal nanofilter. The Fc portion of rFVIIIFc binds to the endogenous neonatal Fc receptor and uses the naturally (physiologically) occurring IgG recycling pathway, delaying lysosomal degradation of Fc-containing proteins by recycling them back into the circulation, thereby resulting in an improved PK profile and extended terminal half-life.

The FVIII component of rFVIIIFc is structurally and functionally comparable to native FVIII, allowing rFVIIIFc to bind to von Willebrand factor (VWF) and phospholipids. B-domain-deleted FVIII contains six glycosylated sites, of which four are conserved in rFVIII products and rFVIIIFc.

Several other Fc fusion proteins have been developed using a similar strategy and are approved for the treatment of several chronic diseases. In contrast to other modified FVIII molecules such as certain PEGylated FVIII molecules, the rFVIII component of rFVIIIFc is fused with the endogenous Fc protein.

2.2 | Pharmacokinetic properties

One-stage clotting assays or chromogenic substrate assays can be used to assess the PK properties of rFVIIIFc. A comparative study of 30 laboratories found the two approaches to be similarly accurate, with marginally higher estimates of plasma rFVIIIFc levels using the chromogenic assay and neither assay requiring a product-specific rFVIIIFc laboratory standard.

PK studies show that rFVIIIFc has reduced clearance compared with rFVIII, but similar incremental recovery and volume of distribution. Consequently, the terminal half-life of rFVIIIFc is, on average, 1.5 times longer than that of an SHL rFVIII product (19.0 vs 12.4 hours for Advate®; Takeda; P < .001). The dose-normalised area under the concentration-time curve was 51.2 (95% confidence interval [CI] 45.0, 58.4) and 32.9 (95% CI 29.3, 36.9) IU·h/dL per IU/kg for rFVIIIFc and Advate, respectively (P < .001). VWF plays a role in extending FVIII survival by protecting it from proteolytic degradation and preventing its binding to FVIII clearance receptors; however, through formation of the VWF/FVIII complex, it also limits the potential for FVIII half-life extension. Indeed, the half-life and clearance of both rFVIIIFc and rFVIII are highly correlated with VWF levels in individual patients, with faster clearance and shorter half-life of rFVIII/ rFVIIIFc in patients with low VWF levels, suggesting that the Fc moiety of rFVIIIFc does not alter the role of VWF in protecting FVIII from clearance. Comparative PK analyses have demonstrated the half-life of rFVIIIFc to be longer than that of rFVIII in individual patients.
Consequently, rFVIIIFc may be administered less frequently than rFVIII to maintain similar FVIII exposure (area under curve), or administered as frequently as rFVIII to attain and maintain higher FVIII levels.\textsuperscript{18} This offers dosing flexibility and allows treatment to be tailored to the individual patient: a standard treatment schedule to maintain higher FVIII levels in more physically active patients or in those with joint damage, and less frequent dosing in patients with venous access problems or difficulty with adherence.\textsuperscript{16,18,19}

As for all FVIII products, age also has an impact on the PK of rFVIIIFc, because the clearance of all FVIII products is greater in younger patients and VWF levels tend to increase with age.\textsuperscript{20-22} The half-life of rFVIIIFc is 12.7 hours in patients aged < 6 years and 14.9 hours in patients aged 6 to < 12 years (but still, on average, 1.5-fold longer than for rFVIII).\textsuperscript{23} For this reason, shorter dosing intervals or higher doses may be needed in children compared with older patients, as already demonstrated for SHL products.\textsuperscript{10,23}

Clinical trial experience and clinical practice have also revealed that patients may be switched from SHL rFVIII products to rFVIIIFc without the need for extensive PK analyses.\textsuperscript{19} However, PK analysis could be of value to confirm improved PK with rFVIIIFc.

3 | SAFETY AND EFFICACY IN PREVIOUSLY TREATED PATIENTS

Two Phase III studies have investigated the safety and efficacy of rFVIIIFc in previously treated patients: A-LONG (NCT01181128)\textsuperscript{16} and Kids A-LONG (NCT01458106).\textsuperscript{23} Patients in both studies were eligible for enrolment in the long-term ASPIRE extension study (NCT01454739).\textsuperscript{24}

A-LONG\textsuperscript{16} was a partially randomised, open-label, multicentre trial of 165 previously treated patients aged ≥ 12 years with severe haemophilia A who were being treated prophylactically or on-demand. Patients who were previously receiving on-demand therapy were eligible for the study if they had experienced ≥ 12 bleeding events in the 12 months prior to the study. The study comprised three treatment arms: individualised prophylaxis, weekly prophylaxis and on-demand treatment. All patients previously on a prophylaxis regimen were enrolled to the individualised prophylaxis arm. Patients who previously received on-demand treatment could choose to be either enrolled to the individualised prophylaxis arm or randomised to either weekly prophylaxis or on-demand treatment. Randomisation was stratified based on individual bleeding episodes in the preceding 12 months. The primary efficacy endpoints were as follows: (i) difference in the per-patient annualised bleeding rate (ABR) between the individualised prophylaxis arm and on-demand arm; and (ii) assessment of FVIII activity based on PK parameters. The primary safety end points were inhibitor development and adverse events (AEs). A surgery subgroup included patients from any arm who required major surgery.

Patients in the individualised prophylaxis arm initially received rFVIIIFc twice weekly (25 IU/kg on Day 1 and 50 IU/kg on Day 4), then 25-65 IU/kg every 3-5 days to achieve a target trough FVIII level of 1-3 IU/dL (n = 118). Patients in the weekly prophylaxis arm received once-weekly rFVIIIFc 65 IU/kg (n = 24). Patients in the on-demand arm received on-demand treatment with rFVIIIFc at a dose of 10-50 IU/kg, depending on bleeding severity (n = 23). The median (min-max) duration of treatment was 32.1 (9-54), 28.0 (< 1-38) and 28.9 (15-32) weeks in the individualised prophylaxis, weekly prophylaxis and on-demand treatment arms, respectively.

Kids A-LONG\textsuperscript{23} was an open-label, multicentre trial involving 71 previously treated patients aged < 12 years with severe haemophilia A and at least 50 exposure days to any recombinant or plasma-derived FVIII product, including cryoprecipitate. The primary end point was the development of inhibitors. Secondary end points included FVIII activity, ABR and location of bleeding. Overall, 69 patients received prophylaxis with twice-weekly rFVIIIFc administered at a dose of 25 IU/kg on Day 1 and 50 IU/kg on Day 4. The dose was subsequently adjusted to a maximum of 80 IU/kg with a minimum administration interval of every 2 days based on bleeding patterns and available PK data. The median time on study was 26.3 weeks.

To evaluate the longer-term safety and efficacy of rFVIIIFc, patients who completed A-LONG or Kids A-LONG were eligible to enter ASPIRE (NCT01454739), a long-term extension study.\textsuperscript{24} This was a non-randomised, open-label extension study that was completed in October 2017. The primary end point was the development of inhibitors. Secondary end points included ABR and rFVIIIFc exposure days. A total of 211 patients (150 from A-LONG and 61 from Kids A-LONG) entered ASPIRE. ASPIRE included four treatment arms (patients aged < 12 years could only participate in the individualised and modified prophylaxis treatment arms) based on the treatment received in A-LONG or Kids A-LONG, with most patients continuing the same treatment regimen in ASPIRE:

- On-demand treatment with rFVIIIFc dosing based on the type and severity of bleeding episodes.
- Individualised prophylaxis with rFVIIIFc 25-65 IU/kg every 3-5 days or twice-weekly rFVIIIFc (20-65 IU/kg on Day 1 and 40-65 IU/kg on Day 4), aiming for a trough level of 1-3 IU/dL. In patients aged < 12 years, the dose could be adjusted to a maximum of 80 IU/kg, with a minimum dosing interval of 2 days.
- Weekly prophylaxis with rFVIIIFc 65 IU/kg.
- Modified prophylaxis if optimal treatment could not be achieved with individualised or weekly prophylaxis; modified prophylaxis involved further personalised dosing to meet patient needs (eg, dosing less frequently, adding “prevention” doses prior to strenuous activity, and targeting a trough FVIII level of > 3 IU/dL).

The modified prophylaxis arm offered the potential for more flexible dosing, taking into consideration the patient’s lifestyle and clinical condition.

Although switching treatment regimens was permitted in ASPIRE, most patients continued the same regimen throughout, with the majority remaining on, or switching to, individualised prophylaxis. For subjects from A-LONG, the cumulative duration of
rFVIIIFc treatment (median [range]) from the beginning of A-LONG to the end of ASPIRE was 4.5 (0.7-5.9) years. For Kids A-LONG to the end of ASPIRE, the cumulative duration of rFVIIIFc treatment (median [range]) was 3.5 (0.4-4.4) years.\textsuperscript{24}

### 3.1 Inhibitor development

The development of inhibitors, defined as a Nijmegen-modified Bethesda assay titre of $\geq 0.6$ BU/mL (confirmed by a second sample within 2-4 weeks), was the primary safety end point in A-LONG and the primary end point in Kids A-LONG and ASPIRE. In these studies of patients with prior prophylactic or on-demand treatment, there were no cases of inhibitor development in A-LONG,\textsuperscript{16,23} Kids A-LONG\textsuperscript{23} or ASPIRE.\textsuperscript{24}

### 3.2 Adverse events

rFVIIIFc was generally well tolerated in A-LONG\textsuperscript{16} and Kids A-LONG,\textsuperscript{23} and during longer-term treatment in ASPIRE.\textsuperscript{26} AEs were similar to those expected in the general and paediatric haemophilia populations and were consistent across settings (eg in patients receiving rFVIIIFc prophylaxis, in patients receiving on-demand treatment with rFVIIIFc and in patients undergoing surgery). AEs related to rFVIIIFc occurred in 10 patients in A-LONG,\textsuperscript{16} 2 patients in Kids A-LONG and 2 patients in ASPIRE.\textsuperscript{23} There were no serious AEs related to rFVIIIFc in these three trials.\textsuperscript{16,23,24} These data indicate that rFVIIIFc is well tolerated by children and adults, and that drug-related AEs are rare in patients with $\geq 100$ exposure days from the start of treatment. Finally, there were no reports of serious allergic reactions or anaphylaxis to rFVIIIFc, or vascular thrombotic events associated with rFVIIIFc, in any of the studies.\textsuperscript{16,23,24}

### 3.3 Prophylactic dosing regimens

#### 3.3.1 A-LONG and ASPIRE

rFVIIIFc consumption was relatively stable throughout A-LONG and ASPIRE, with no change in median weekly factor consumption from the end of A-LONG to the end of ASPIRE.\textsuperscript{24}

Among patients in the individualised prophylaxis arm in A-LONG, the median dosing interval was 3.5 days in the last 3 months of the study, and 99% received rFVIIIFc at least every 3 days.\textsuperscript{16} The median (min, max) weekly total dose was 77.9 (54.0, 141.5) IU/kg/week among patients who administered rFVIIIFc every 3-5 days in the individualised prophylaxis arm and 65.6 (59.4, 70.7) IU/kg/week in the weekly prophylaxis arm.\textsuperscript{16} Almost all (98.8%) of the patients in the individualised prophylaxis arm who were previously on FVIII prophylaxis decreased their injection frequency compared with their prestudy regimen (Table 1).\textsuperscript{19}

From the end of A-LONG to the end of ASPIRE, the dosing interval was maintained in 71%, increased in 21% and shortened in 8% of patients.\textsuperscript{24}

#### 3.3.2 Kids A-LONG and ASPIRE

In Kids A-LONG, the median (interquartile range [IQR]) rFVIIIFc dosing interval was 3.5 (3.5-3.5) days and the median (IQR) weekly dose was 88 (80-103) IU/kg.\textsuperscript{23} In total, 59 children completed at least 24 weeks on study, and their median (IQR) dosing interval and

### Table 1

| FVIII prestudy injection frequency | N  | Number of annual injections, prestudy estimate | rFVIIIFc dosing interval, last on study | n (%)\textsuperscript{a} | Number of annual injections, on-study estimate | Approximate change in annual injections (%) |
|-----------------------------------|----|-----------------------------------------------|---------------------------------------|-----------------|-----------------------------------------------|---------------------------------------------|
| Twice weekly                      | 9  | 104                                           | Every 5 d                             | 8 (88.9)        | 73                                            | −29.8                                       |
|                                   |    |                                               | Every 3 d\textsuperscript{b}          | 1 (11.1)        | 122                                           | +17.3                                       |
| Three times weekly                | 65 | 156                                           | Every 3 d                             | 24 (36.9)       | 122                                           | −21.8                                       |
|                                   |    |                                               | Twice weekly                          | 22 (33.8)       | 104                                           | −33.3                                       |
|                                   |    |                                               | Every 4 d                             | 4 (6.2)         | 91                                            | −41.7                                       |
|                                   |    |                                               | Every 5 d                             | 15 (23.1)       | 73                                            | −53.2                                       |
| Four times weekly                 | 5  | 208                                           | Every 3 d                             | 4 (80.0)        | 122                                           | −41.3                                       |
|                                   |    |                                               | Twice weekly                          | 1 (20.0)        | 104                                           | −50.0                                       |
| Five times weekly                 | 1  | 260                                           | Every 5 d                             | 1 (100.0)       | 73                                            | −71.9                                       |

Abbreviations: ABR, annualised bleeding rate; FVIII, factor VIII; rFVIIIFc, recombinant factor VIII Fc.

\textsuperscript{a}Percentages refer to the proportion of subjects from each prestudy dosing group who converted to the specified on-study regimen.

\textsuperscript{b}Examination of prestudy and on-study bleeding rates indicated that the patient was not dosed appropriately prestudy to manage breakthrough bleeds since the prestudy bleeding rate was 42.0, overall on-study ABR was 7.5, and ABR in the last 3 mo on study was 0.0.
weekly dose in the last 3 months were 3.5 (3.5-3.5) days and 93 (80-109) IU/kg, respectively. Although the median dose was slightly higher in children aged < 6 years, the median dosing interval was 3.5 days in all children (< 6 and 6-12 years). Overall, 46 out of 62 patients (74.2%) had a reduced dosing frequency with rFVIIIFc compared with their previous FVIII prophylaxis regimen.23 From the end of Kids A-LONG to the end of ASPIRE, dosing interval was maintained in 89%, increased in 7% and shortened in 5% of patients.24

3.4 | Efficacy

ABR was the primary efficacy end point in A-LONG (difference in per-patient ABR between the individualised prophylaxis arm and on-demand arm)16 and a secondary end point in Kids A-LONG.23 ABR was also assessed over long-term treatment in ASPIRE.24

In A-LONG, ABR was significantly reduced by 92% and 76% in patients receiving prophylaxis with rFVIIIFc in the individualised prophylaxis and weekly prophylaxis arms, respectively, compared with that in patients receiving on-demand treatment.16

Among 72 patients in the individualised prophylaxis arm and 21 patients in the weekly prophylaxis arm who had target joints (defined as major joints with history of ≥ 3 bleeding episodes into the same joint in a 6-month period)25 at entry into A-LONG, the median (IQR) target joint ABR during rFVIIIFc prophylaxis was 0.0 (0.0-3.0) and 0.0 (0.0-1.9), respectively.26

Overall, spontaneous, traumatic and joint ABRs in A-LONG and ASPIRE are summarised in Table 2 and demonstrate the consistently low ABRs among patients on rFVIIIFc prophylaxis, including a median spontaneous joint ABR of zero with individualised prophylaxis both in A-LONG and ASPIRE.

As in adults, the overall ABR was low in patients aged < 12 years who received rFVIIIFc prophylaxis in Kids A-LONG, with a median (IQR) of 1.96 (0.0-3.96) for all children, 0.00 (0.0-3.96) in children aged < 6 years and 2.01 (0.0-4.04) in children aged 6 to < 12 years. In both age groups, the median (IQR) spontaneous joint ABR was 0.0 (0.0-0.0).23 Among children with ≥ 1 target joint (also defined as major joints with history of ≥ 3 bleeding episodes into the same joint in a 6-month period), the median (IQR) overall ABR was lower on study compared with the prestudy value (0.0 [0.0-0.5] vs 8.0 [4.0-11.0]; n = 13). In children with no target joints, the median ABR remained constant from the prestudy value to the on-study value (n = 56; Figure 3).

During longer-term treatment, ASPIRE showed that ABR in adults and children of all ages remained low, consistent with the initial reports of A-LONG and Kids A-LONG.24

In A-LONG, 45% of patients in the individualised prophylaxis arm did not experience any bleeding episodes, versus 17% in the weekly prophylaxis arm.16 In Kids A-LONG, 46% of children did not experience any bleeding episodes during the study.23

Most bleeding episodes in A-LONG, Kids A-LONG and ASPIRE were resolved with one or two rFVIIIFc injections (Figure 4). In A-LONG, 87% of bleeding episodes involving target joints were resolved with one rFVIIIFc injection, and 98% of bleeding episodes involving target joints were resolved with up to two rFVIIIFc injections.26 In ASPIRE, more than 75% of acute bleeding episodes were controlled by one injection of rFVIIIFc, and more than 93% of bleeds with two or less injections.24

In adults and adolescents in A-LONG, the median dose of rFVIIIFc needed to treat a bleeding episode was 27 IU/kg, and among patients who received individualised prophylaxis, weekly prophylaxis and on-demand treatment, the median dose was 33, 30 and 27 IU/kg,

### Table 2: ABRs in A-LONG and ASPIRE

| Median (IQR) ABR | Individualised prophylaxis | Weekly prophylaxis | Modified prophylaxis |
|------------------|----------------------------|--------------------|----------------------|
| A-LONG 16        |                            |                    |                      |
| Overall          | 1.6 (0.0-4.7)              | 3.6 (1.9-8.4)      | n/a                  |
| Spontaneous      | 0.0 (0.0-2.0)              | 1.9 (0.0-4.8)      | n/a                  |
| Traumatic        | 0.0 (0.0-1.8)              | 1.7 (0.0-3.3)      | n/a                  |
| Spontaneous joint| 0.0 (0.0-1.7)              | 0.0 (0.0-3.8)      | n/a                  |
| Traumatic joint  | 0.0 (0.0-1.2)              | 0.0 (0.0-2.0)      | n/a                  |
| Spontaneous muscle| 0.0 (0.0-0.0)              | 0.0 (0.0-0.0)      | n/a                  |
| Traumatic muscle | 0.0 (0.0-0.0)              | 0.0 (0.0-0.0)      | n/a                  |
| ASPIRE* 24       |                            |                    |                      |
| Overall          | 0.7 (0.0-2.7)              | 2.2 (0.4-5.1)      | 4.1 (1.2-8.8)        |
| Spontaneous      | 0.1 (0.0-1.1)              | 1.5 (0.0-2.7)      | 1.4 (0.4-3.9)        |
| Traumatic        | 0.2 (0.0-1.1)              | 0.5 (0.2-1.0)      | 0.9 (0.2-3.0)        |
| Joint            | 0.5 (0.0-1.7)              | 1.7 (0.4-3.6)      | 1.7 (0.6-7.6)        |
| Spontaneous joint| 0.0 (0.0-0.7)              | 1.0 (0.0-2.5)      | 1.0 (0.0-2.8)        |

Abbreviations: ABR, annualised bleeding rate; n/a, not applicable.

*ABRs in subjects from the A-LONG parent study.
In Kids A-LONG, a higher median dose of 50 IU/kg was needed per bleeding episode.\textsuperscript{23} Effects on physical activity and HRQoL

In A-LONG and Kids A-LONG, 87% of patients on prophylaxis reported being able to maintain the same level of activity or increase their activity level during the study compared with their prestudy activity level (Figure 5).\textsuperscript{27}

The impact of rFVIIIFc on HRQoL was assessed in 67 patients who completed the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL), including 57 on individualised prophylaxis, three on weekly prophylaxis and seven on on-demand treatment.\textsuperscript{28} Among patients who received individualised prophylaxis, 24%, 47% and 36% were classified as responders in terms of their improvements in total score, the physical health domain, and the sports and leisure domain, respectively, defined as a 7-point reduction in total score or a 10-point reduction in the physical health and sports and leisure domains. The mean (standard deviation) changes from baseline to Week 28 in the A-LONG study for patients receiving individual prophylaxis were $-3.2 \pm 9.9$ ($n = 46; P = .034$) for total score, $-7.0 \pm 22.2$ ($n = 57; P = .02$) for the physical health domain and $-4.5 \pm 20.8$ ($n = 39$) for the sports and leisure domain. There were no significant differences in any of these scores (total, physical health, and sports and leisure) for patients who had received weekly prophylaxis or on-demand treatment, although these groups only
included small populations. Evaluation of patients receiving individual prophylaxis by prestudy treatment showed that those receiving prestudy on-demand treatment had larger reductions than those receiving prestudy prophylaxis. In the third interim data analysis of the open-label extension study ASPIRE, HRQoL was evaluated in a population of 80 adult patients from the A-LONG study who enrolled in the ASPIRE study and had total change scores from baseline to Month 24 in the ASPIRE study. The improvements in HRQoL scores reported in patients in the ALONG study were maintained during longer-term treatment, with the mean total Haem-A-QoL score showing a significant reduction versus A-LONG baseline at all time points (Figure 6A). Similar findings were reported for the individual domains of physical health, sports and leisure, and feeling, with some significant differences being reported (Figure 6).29

**FIGURE 6** Mean changes in Haem-A-QoL scores (A and B) from baseline in A-LONG to Mo 24 of ASPIRE.29 (A) Mean (standard error) change in Haem-A-QoL score in the individualised prophylaxis arm in ASPIRE; (B) Mean (standard error) changes in the physical health, sports and leisure, and feeling domains in the individualised prophylaxis arm in ASPIRE. (A/B): *P ≤ .01 compared with A-LONG baseline score. NB. Data presented in graphs are mean (standard error) while data in the supporting tables for (A) and (B) are mean (standard deviation). Abbreviations: Haem-A-QoL, Haemophilia Quality of Life Questionnaire for Adults; n, number of observations at ASPIRE Mo 24 [Colour figure can be viewed at wileyonlinelibrary.com]
3.6 | Effects on joint health

Spontaneous musculoskeletal bleeding is a common symptom in patients with severe haemophilia, and intra-articular bleeding can result in synovial hypertrophy and haemophilic arthropathy. The primary aim of prophylaxis is to prevent joint damage; therefore, it is important to investigate the effects of FVIII prophylaxis on joint health in patients with haemophilia A.

Rates of target joint resolution were assessed in 111 patients in A-LONG and in 13 patients in Kids A-LONG, with evaluable target joints who subsequently enrolled in ASPIRE. During the studies, resolution (defined as ≤ 2 spontaneous bleeding episodes in the target joint over 12 consecutive months for all three studies) was achieved in 99.6% of evaluable target joints in A-LONG and 100% of evaluable target joints in Kids A-LONG.

From A-LONG baseline through to ASPIRE Year 2, joint health was also assessed in 47 patients using a modified version of the Haemophilia Joint Health Score (mHJHS). This modified version of the HJHS was developed for adult patients and differs from the original HJHS version 2.1 (primarily designed for children aged 4-18 years) in terms of crepitus of motion (HJHS vs mHJHS: 0-2 vs 0-1), joint pain (0-2 vs 0-1) and global gait (0-4 vs 0-2) scores. Moreover, a score for instability has been added (0-1). Consequently, the total score range is also different (0-124 vs 0-116). Higher scores indicate worse disease. Up to now, this modified version has not been validated.

These post hoc analyses revealed a significant (P = .001) improvement from A-LONG baseline to ASPIRE Year 2 among 47 evaluable patients (24 of whom had target joints at baseline) receiving treatment with rFVIIIFc. When the data were stratified by previous treatment, the magnitude of improvement in mHJHS was also significant in the group previously receiving on-demand treatment (n = 17, P = .003), but not in those previously receiving prophylaxis (n = 30, P = .09).

However, these findings may be limited by the small sample size, short duration of follow-up, inter-observer variability and the fact that the mHJHS has not yet been validated for clinical use.

3.7 | Use in peri-operative management

In an analysis of surgeries occurring in subjects enrolled in A-LONG, Kids A-LONG and ASPIRE, 46 major surgeries were performed in 32 patients and in 90 minor surgeries in 70 patients. A total of 44 major surgeries had information on rFVIIIFc administration on the day of surgery (33 orthopaedic and 11 non-orthopaedic).

Most major surgeries (87%) required ≤ 1 injection of rFVIIIFc (including loading dose) to maintain haemostasis during surgery (loading dose was defined as the first dose used on the day of surgery, or the dose used 1 day prior if there was no dose on the day of surgery). The haemostatic responses were rated as excellent or good in all the 42 evaluable major surgeries (excellent: n = 39, ie haemostasis comparable to what could be expected for individuals without haemophilia; good: n = 3, ie prolonged time to haemostasis with somewhat increased bleeding compared with individuals without haemophilia). For major surgery, median (range) rFVIIIFc total dose on the day of surgery to maintain haemostasis was 81 (39-158) IU/kg in patients from A-LONG and 38-66 IU/kg in two patients from Kids A-LONG; on the day of minor surgery in patients from A-LONG and Kids A-LONG, median (range) total consumption was 52 (25-112) and 88 (53-216) IU/kg, respectively. Continuous infusion was not permitted.

Eighty-nine percent of minor surgeries required ≤ 1 injection of rFVIIIFc (including loading dose) to maintain haemostasis during surgery. The haemostatic response was rated as excellent (85%) or good in all evaluable minor surgeries (excellent: n = 55; good: n = 10, as previously defined).

4 | rFVIIIFC IN CLINICAL PRACTICE

There is growing clinical experience supporting the efficacy and safety of rFVIIIfc in patients with haemophilia A. Numerous observational studies and case series have now been published, which consistently show a reduced frequency of dosing or a reduction in FVIII consumption, with the same or decreased bleeding following a switch to rFVIIIfc. Switching to rFVIIIfc was generally well tolerated. Notably, in line with clinical trial data, in publications that reported inhibitor outcomes, no previously treated patients without previous inhibitors developed inhibitors to rFVIIIfc in patients previously tolerised on another FVIII product showed no recurrence of inhibitor after switch to rFVIIIfc. Although no major concerns exist for patients who switched from other FVIII products, lifelong surveillance for inhibitor development is recommended in all previously tolerised patients irrespective of factor concentrate used.

Finally, some observational studies and case reports have investigated the outcomes of using rFVIIIfc in patients with haemophilia A undergoing major surgery. The authors reported that rFVIIIfc provided effective haemostasis in major surgery without significant bleeding; data are summarised in Table 3.

4.1 | Ongoing studies in real-world clinical practice

To provide further insight into the safety and efficacy of rFVIIIfc in clinical practice, several non-interventional, observational studies have been started in Europe, North America and Japan, as detailed in Table 4.

5 | PREVIOUSLY UNTREATED PATIENTS

The A-LONG, Kids A-LONG and ASPIRE studies enrolled patients with previously treated haemophilia A who switched from
| First author | Study type  | Patient(s)                                      | FVIII levels/dosing                                                                                     | Outcomes                                                                                                    |
|--------------|-------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Hellal M     | Case study  | 64-y-old with severe haemophilia A undergoing ankle fusion surgery | 6000 IU (64 IU/kg) rFVIIIFc 1 h presurgery  
Peak FVIII level postinjection: 129 IU/dL  
FVIII level 6 h post-treatment: 112 IU/dL | No breakthrough/postoperative bleeding was reported                                                      |
| Abraham A    | Observational cohort | 21 patients with haemophilia A undergoing major surgery (16 orthopaedic surgeries) | Median (range) total rFVIIIFc used: 151 (123-563) IU/kg (once daily); 388.5 (182-707) IU/kg (twice daily) | 9 patients required 1 transfusion of packed red cells each, in accordance with expected blood loss in those surgeries  
No other blood product transfusion was required                                                      |
| Apte S       | Observational cohort | 24 patients with severe haemophilia A undergoing total knee replacement surgery | Presurgery: 50 IU/kg  
Post surgery: 40-50 IU/kg once daily until D 5, then 30 IU/kg once daily until D 15 | 23 patients had no significant intra- or postoperative bleeding, and no transfusion support was needed  
1 patient also undergoing pseudo-tumour excision required an extra 50 IU/kg rFVIIIFc and 8 transfusions of packed red cells and 10 of cryoprecipitate for a total blood loss of 2200 mL, as expected; he experienced no postoperative bleeding before discharge |
| Kremer H     | Case study  | 3-y-old patient with severe haemophilia A undergoing central venous catheter replacement | 60 IU/kg bolus presurgery and continuous infusion of 4 IU/kg/h  
To maintain FVIII levels 80-100 IU/dL on D 1 and 2 post surgery and 50-80 IU/dL on D 3-5; total dose of rFVIIIFc used during surgery period was 472 IU/kg (over 7 d; average of 67 IU/kg/d) | No haemorrhage or complications occurred during continuous infusion³ |
| Lienhart A   | Observational cohort | 13 patients with haemophilia A undergoing surgery (8 major, 5 minor) | Average total FVII-Fc consumption on the d of surgery was 84.5 IU/kg for major surgeries and 44.5 IU/kg for minor surgeries; in the postoperative wk, it was 44 IU/kg/d for major surgeries and 17 IU/kg/d for minor surgeries | Blood loss was as expected for these surgeries                                                                 |
| Okamoto A    | Case study  | 28-y-old patient with haemophilia A undergoing cranial surgery | 4000 IU (50 IU/kg) rFVIIIFc 1 h presurgery (D 0), then 45 IU/kg on D 1, 30 IU/kg on D 2, 25 IU/kg/d on D 3-7 and 15 IU/kg/d on D 8-12 | 150 mL blood loss, as expected for this surgery; two occurrences of mild nasal bleeding; patient was discharged on schedule |
| Fujii T      | Case studies | 2 patients with severe haemophilia A each with 2 surgeries, 1 managed with SHL-FVIII and 1 with rFVIIIFc. Patient 1 had 2 orthopaedic surgeries (knee and hip arthroplasty); patient 2 had hepatectomies | Patient 1: Total factor consumption during perioperative period was 600 IU/kg for SHL-FVIII and 242 IU/kg for rFVIIIFc  
Patient 2: 780.7 IU/kg for SHLFVIII and 487.7 IU/kg for rFVIIIFc | There was less total blood loss with rFVIIIFc than with SHL-FVIII for patient 2                          |

Abbreviations: FVIII, factor VIII; FVIII-Fc, factor VIII Fc; h, hour; rFVIIIFc, recombinant factor VIII Fc; SHL-FVIII, standard half-life factor VIII.

³Dosing guidance for continuous infusion is not included within the label.
| Study name (ClinicalTrials.gov identifier) | Design | Patient population | Location | Therapy | Primary objective | Status |
|------------------------------------------|--------|---------------------|----------|---------|-------------------|--------|
| PREVENT (NCT03055611)                   | Prospective, non-interventional, multicentre, 24-mo study | 198 previously treated patients with haemophilia A or B | Germany | Prophylaxis with rFVIIIFc or rFIXFc | To describe the real-world usage and effectiveness of rFVIIIFc and rFIXFc treatment over a 24-mo period | Active, not recruiting |
| A-SURE 58 (NCT02976753)                 | Prospective, non-interventional, multicentre, Phase IV, 24-mo study | 358 previously treated patients with haemophilia A receiving FVIII prophylaxis | Europe | Patients prescribed prophylaxis with rFVIIIFc matched with patients receiving SHL FVIII products | To compare the effectiveness of prophylaxis with rFVIIIFc vs SHL FVIII products in patients with haemophilia A over a 24-mo period | Active, not recruiting |
| Factor utilisation and health outcomes study (NCT02796222) | Prospective, non-interventional, multicentre, 24-mo study | ~120 patients with haemophilia A or B switching from rFVIII or rFIX to rFVIIIFc or rFIXFc, and patients who remain on rFVIII or rFIX | Canada | On-demand treatment/ prophylaxis with rFVIIIFc or rFIXFc or on-demand treatment/prophylaxis with rFVIII or rFIX | Annualised factor consumption over a 24-mo period | Recruiting, started April 2016 |
| ATHN 2: factor-switching study (NCT02546622) | Prospective and retrospective arms, non-interventional, multicentre, 12-mo study | 310 patients with haemophilia A or B switching to a newly approved coagulation factor replacement product, or who have recently switched factor products | USA | rFVIII or rFIX replacement products for haemophilia | To determine the rate of inhibitor development at 1 y or 50 exposure days (whichever comes first) | Completed, final results not yet reported |
| Musculoskeletal health study (NCT03914209) | Prospective, non-interventional, multicentre, 12-mo study | ~40 patients with haemophilia A | Spain | Prophylaxis with rFVIIIFc | Bleeding frequency over 12 mo | Not yet recruiting |
| A-MORE (NCT04293523)                    | Prospective, non-interventional, multicentre, 48-mo study | ~300 patients with haemophilia A | Europe | Prophylaxis with rFVIIIFc | To evaluate the long-term effectiveness of rFVIIIFc prophylaxis on joint health over a 48-mo period | Recruiting |

Abbreviations: FVIII, factor VIII; rFIX, recombinant factor IX; rFIXFc, recombinant factor IX Fc; rFVIII, recombinant factor VIII; rFVIIIFc, recombinant factor VIII Fc; SHL, standard half-life.
To rFVIIIFc. Likewise, the publications describing experience and outcomes with rFVIIIFc in clinical practice involved patients switching to rFVIIIFc.

The open-label, multicentre, Phase III PUPs A-LONG study (NCT02234323) evaluated safety, including inhibitor development, and efficacy of rFVIIIFc in 103 male previously untreated patients aged <6 years with severe haemophilia A. The study demonstrated that rFVIIIFc was well tolerated and effective in this patient population. The total inhibitor incidence was 31.1% (28/90) in patients with ≥10 exposure days or who had an inhibitor, in line with expected rates for FVIII products, whereas the incidence of high-titre inhibitors (≥5 BU/mL), at 15.6%, was lower than previously reported.59-61 The median (range) time to inhibitor development was 9 (1-53) exposure days. In 89 patients who received a prophylactic regimen, the median (IQR) weekly dose was 101.44 (62.98, 138.68) IU/kg and median interval (IQR) was 3.87 (3.28, 4.74) days. Median ABRs (IQR) in patients treated with episodic and prophylactic regimens were 2.24 (0.00, 5.94) and 1.49 (0.00, 4.40), respectively.59

6 | TOLERANCE INDUCTION

About one-third of previously untreated patients with severe haemophilia A develop inhibitors to FVIII products, which have a significant impact on treatment and outcomes, including increased mortality.60,62,63

Some patients with low inhibitor titres can be managed by administering higher doses of FVIII, but patients with high titres require bypassing agents such as activated prothrombin complex concentrate or recombinant factor VIIa to control or prevent bleeding episodes, or emicizumab to prevent bleeding episodes.64,65 Eradication of inhibitors remains the preferred treatment strategy for these patients in order to restore haemostatic efficacy of replacement therapy.65 This is achieved by immune tolerance induction (ITI) therapy, which involves frequent and regular injections of FVIII concentrates over a period of months to years and is effective in about two-thirds of patients with inhibitors.65

Several preclinical studies have indicated that rFVIIIFc may have relatively low immunogenicity and may be able to induce tolerance in animal models66,67 and it has been proposed that rFVIIIFc could improve immune tolerance in patients with inhibitors.65,68 In terms of the likely mechanism, it has been speculated that the IgG Fc component of rFVIIIFc drives the immunomodulatory effects of rFVIIIFc because specific T-cell epitopes in the Fc domain activate a subset of regulatory T cells that tip the resulting immune response towards tolerance.69

The use of rFVIIIFc in ITI has been examined in case reports70,71 and small cohort studies.72,73 For example, in one case study of three children with severe haemophilia A and inhibitors (one of whom had a failed previous ITI attempt), when treated with rFVIIIFc, all three seemed to respond relatively rapidly and at
lower dose frequency compared with SHL rFVIII ITI, and tolerance was achieved in two patients (the third patient had no detectable anti-FVIII antibody after 2.8 months but a FVIII recovery of 57%, below the predetermined 60% threshold for tolerance). In a retrospective chart review, 9 out of 10 patients undergoing first-time ITI with rFVIIIFc (regimens ranging from 50 IU/kg three times per week to 200 IU/kg once daily) were tolerised, and 10 out of 19 rescue ITI patients reached negative titre, of whom 4 were tolerised (although 1 subsequently relapsed). In a report of interim outcomes for 38 paediatric and adult patients with haemophilia A and inhibitors ≥ 0.6 BU/mL who underwent ITI with rFVIIIFc in India (regimens ranging from 50 IU/kg three times per week to 200 IU/kg per day), the median (range) duration of inhibitors prior to ITI was 2 (0.1-20) years. Preliminary data show that 17 patients (45%) achieved a negative inhibitor titre after ITI for a median (range) duration of 23 (10-64) weeks, although negative inhibitor titre does not equate to inhibitor eradication.

Two prospective, open-label, single-arm, interventional, multi-centre studies are now under way to examine the efficacy of rFVIIIFc in ITI (Table 5). The verITI-8 study (NCT03093480) is assessing time to tolerisation with rFVIIIFc over a 48-week period in 16 patients undergoing primary ITI treatment. Interim results showed that 6 out of 14 enrolled patients had been successfully tolerised, with a median (range) time to tolerisation of 11.7 (8.1-32.0) weeks. Meanwhile, the ReITIrate study (NCT03103542) will assess the rate of ITI success with rFVIIIFc over a 60-week period in 16 patients undergoing rescue ITI therapy having had at least one previous failed ITI attempt.

7 | EXPERT OPINION

7.1 | Potential benefits of rFVIIIFc therapy and considerations for treatment

rFVIIIFc proved to be effective and well tolerated in previously treated patients with haemophilia A, providing low ABRs, target joint resolution, improved orthopaedic scores and no new cases of inhibitor development. rFVIIIFc was also associated with improvements in HRQoL. These results highlight several possible benefits for patients switching to rFVIIIFc in terms of individualisation of treatment with increased treatment flexibility and treatment tailoring to individual needs compared with SHL FVIII products. We believe that this is important in clinical practice owing to the phenotypic heterogeneity of haemophilia A and varying individual patient lifestyles. Moreover, treatment individualisation from childhood might allow better haemostatic control to avoid joint bleeding, including subclinical bleeds, and to prevent the development of joint damage in the long term. As illustrated in Figure 7, the dosing of rFVIIIFc can be tailored according to the patient’s age and lifestyle, desire for increased protection and fewer injections, and clinical factors such as clinical phenotype.

Individualised prophylaxis may permit treatment intensification depending on the patient’s needs. For example, highly active patients may benefit from more frequent prophylactic doses to avoid the risk of bleeding during sports or other activities, whereas patients with venous access limitations may prefer fewer injections to maintain minimal trough rFVIIIFc activity levels.

**FIGURE 7** Triad of clinical factors that influence individualised prophylaxis with rFVIIIFc aiming for zero bleeding events in patients with severe haemophilia A. Abbreviation: rFVIIIFc, recombinant factor VIII Fc [Colour figure can be viewed at wileyonlinelibrary.com]
The Kids A-LONG study demonstrated that rFVIIIFc prophylaxis has the potential to reduce administration frequency compared with SHL rFVIII products. rFVIII prophylaxis in children often necessitates insertion of a central venous access device because of the difficulty of injecting the factor concentrate through peripheral veins. As rFVIIIFc can be administered less frequently in prophylaxis, it might be possible to avoid central venous access device insertion. Nevertheless, some highly active children may benefit from more frequent rFVIIIFc dosing to minimise their bleeding risk during sports or other activities.

By tailoring the administration of rFVIIIFc to the individual patient, it may be possible to achieve a very low rate of, or even no, bleeds in a large proportion of patients with severe haemophilia A.

7.2 Strategies for successfully initiating rFVIIIFc in patients with severe haemophilia A

A switch from rFVIII to rFVIIIFc may benefit patients differently depending on their needs. PK simulations suggest that switching to rFVIIIFc at the same dose and dosing frequency as the previous SHL FVIII prophylaxis will lead to higher trough levels in most patients. Dosing can thereafter be adjusted based on individual needs. If the goal is fewer injections, a conservative approach could be to prescribe a similar total weekly factor dose, but to administer one injection fewer per week. A patient already well controlled on rFVIII prophylaxis could potentially benefit from reduced injection frequency and decreased rFVIII consumption. In a patient who is not optimally covered by prophylaxis with SHL rFVIII, it may be possible to keep the injection frequency and dose the same as for prior rFVIII treatment to benefit from improved bleed control.

Assessment of FVIII levels is universally used to guide dosing, which many clinicians do by testing the trough FVIII level and monitoring the patient’s clinical response. In some clinics, however, treaters may want to perform more extensive PK testing at the time of switching to rFVIIIFc. Given that full dense-sampling PK studies are burdensome, reduced-sampling protocols using population (Bayesian) PK calculation tools such as the WAPPS-Hemo tool (https://www.wapps-hemo.org/) can help to predict the PK of rFVIIIFc and make informed dosing decisions, and these have already been used for a large number of patients worldwide. A proportion of patients may be treated once weekly, and post hoc analyses have demonstrated a correlation between VWF levels and prolongation of half-life that might be helpful in the identification of patients who may benefit most from the PK characteristics of rFVIIIFc.

7.3 Research gaps

In Ireland, rFVIIIFc is available for all patients, including those who are previously untreated. The PUPs A-LONG study is the first to evaluate use of an extended half-life rFVIII product in previously untreated patients, and demonstrated rates of inhibitor development, including high-titre inhibitors, which were consistent with or lower than rates reported for SHL FVIII products. Further data are required to help haematologists determine the optimal strategy, including timing of initiation, for starting rFVIIIFc in previously untreated patients.

Data on long-term outcomes in clinical practice such as FVIII consumption, joint status and quality of life are also needed. The ongoing A-SURE, PREVENT and A-MORE studies include relevant end points (Table 4).

The verITI-8 and ReITirate studies have been designed to investigate the role of rFVIIIFc in ITI therapy in both ITI-naive and -experienced patients. These studies should provide valuable data on the efficacy of rFVIIIFc in ITI therapy.

Following the use of rFVIIIFc in developing countries as part of the World Federation of Hemophilia Humanitarian Aid Program, some data have been reported that show reduced frequency of dosing or a reduction in FVIII consumption, with maintained or decreased bleeding, when switching to rFVIIIFc, and further data are anticipated.

Considering that A-LONG and Kids A-LONG enrolled patients with severe haemophilia A, studies of patients with mild and moderate haemophilia A switching from on-demand use of other FVIII products to rFVIIIFc would also be valuable. In Ireland, there has been clinical experience of this in patients with no issues encountered (Nolan B, unpublished observations). Continued follow-up of these patients, including inhibitor development, will help inform clinical practice.

Research is ongoing to further improve the PK profile of rFVIIIFc. In this regard, BIVVO01 (rFVIIIFc-VWF-XTEN), a novel fusion protein comprising a VWF-D’D3 domain fused to rFVIII via immunoglobulin G1 Fc domains and two XTEN® polypeptides, has been designed. It has been shown in animal studies not to bind endogenous VWF and to have a four-fold extended half-life compared with SHL FVIII. Once-weekly prophylaxis may be possible based on data from a Phase I/IIa study in adults with severe haemophilia A in which the half-life of BIVVO01 was 37.6 hours (vs 9.1 hours for rFVIII) among patients receiving a single 25 IU/kg dose, and 42.5 hours (vs 13.2 hours for rFVIII) among those receiving a single 65 IU/kg dose. The average residual FVIII level was 5% at 7 days after BIVVO01 injection for the 25 IU/kg dose and 17% for 65 IU/kg, with no inhibitors detected for either dose.

8 Conclusions

Clinical trials and clinical experience demonstrate that rFVIIIFc provides effective prophylaxis for previously treated patients with severe haemophilia A and is generally well tolerated. The safety and efficacy of long-term treatment (up to 5.9 years) with rFVIIIFc have been demonstrated in the Phase III ASPIRE extension study. The studies also showed that rFVIIIFc can be used to manage bleeding events and to maintain peri-operative haemostasis in patients with haemophilia A. Some data suggest that rFVIIIFc prophylaxis might
also confer better joint protection than previous rFVIII treatment, although further data are needed to confirm these observations. rFVIIIFc allows broader treatment flexibility and treatment individualisation compared with SHL FVIII products. The flexibility provided by rFVIIIFc extends to the ability to adapt the prophylaxis regimen according to the individual patient's activity, joint status and quality of life, with the potential to intensify or even de-escalate the treatment regimen as appropriate for that patient. In this way, it may be possible to address the phenotypic heterogeneity of haemophilia A. In addition, patients using rFVIIIFc could require fewer injections than with SHL FVIII products, which may reduce the burden of treatment and potentially improve adherence. In summary, rFVIIIFc is suitable for use in individualised prophylaxis regimens that can be tailored according to the patient's age, clinical needs, lifestyle and wishes.

ACKNOWLEDGMENTS
All authors were involved in planning the scope of this review article, analysis of the relevant literature, clinical interpretation of data presented, and critical review of the text and provided their final approval of the version of the article to be published. The manuscript was reviewed by Sobi and Sanofi. Medical writing support was provided by Gillian Keating MBChB from Mudskipper Business Limited, funded by Sobi.

CONFLICT OF INTEREST
CH has received speaker fees or honoraria for consultancy or advisory boards from Takeda, Pfizer, Bayer, Octapharma, LFB, CAF-DCF, Roche, Novo Nordisk, CSL Behring, Sobi, Biogen and Biomarin. MEM has acted as a paid consultant/advisor/speaker for Bayer Healthcare, CSL Behring, Novo Nordisk, Roche, Sobi, Takeda, Octapharma, Pfizer, Kedrion, Grifols, Biomarin, Catalyst and Bioverativ. BN has received speaker fees from Sobi and led sponsored clinical trials for Sanofi, Sobi, Bioverativ, Biogen, CSL Behring and Bayer. KJP has received speaker fees or honoraria for consultancy or advisory boards from Biotest, Takeda, Pfizer, Octapharma, Biomarin, Catalyst Bio, Roche, Novo Nordisk, Sobi, Apicintex and Sanofi.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analysed in this study.

ORCID
Cedric Hermans https://orcid.org/0000-0001-5429-8437

REFERENCES
1. Fischer K, Ljung R. Primary prophylaxis in haemophilia care: Guideline update 2016. Blood Cells Mol Dis. 2017;67:81-85.
2. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020; 26(Suppl 6): 1-158.
3. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: A beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329-335.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535-544.
5. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7:392-396.
6. Oldenburg J. Optimal treatment strategies for hemophilia: Achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038-2044.
7. Mancuso ME, Mannucci PM. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. Drug Des Devel Ther. 2014;8:365-371.
8. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031-3037.
9. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413-420.
10. Swedish Orphan Biovitrum Ltd. Elotra powder and solvent for solution for injection: summary of product characteristics. 2016.
11. Leksa NC, Chiu PL, Bou-Assaf GM, et al. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein. J Thromb Haemost. 2017;15:1167-1179.
12. McCue J, Kshirsagar R, Selvitielli K, et al. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals. 2015;43:213-219.
13. Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013;11:132-141.
14. Cavaco M, Castanho M, Neves V. Peptidodies: An elegant solution for a long-standing problem. Biopolymers. 2017; https://doi.org/10.1002/bip.23095
15. Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia. 2014;20(Suppl 4):23-28.
16. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317-325.
17. Sommer JM, Moore N, McGuffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014;20:294-300.
18. Berntorp E, Negrer C, Gozzi P, Blaa PM, Lethagen S. Dosing regimens, FVIII levels and estimated haemostatic protection with specific focus on rFVIIIc. Haemophilia. 2016;22:389-396.
19. Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014;12:1788-1800.
20. Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018;24:348-358.
21. Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther. 2013;13:1287-1297.
22. Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia. 2015;21:636-641.
23. Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967-977.
24. Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020;26:494-502.

25. Blanchette VS, Key NS, Jlung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935-1939.

26. Shapiro AD, Mahlangu JN, Perry D, et al. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017;23:392-399.

27. Quon DV, Klamroth R, Kulkarni R, et al. Low bleeding rates with recombinant factor VIII Fc fusion protein (rFVIII-Fc) in the A-LONG and Kids A-LONG studies. Haemophilia. 2017;23:e39-e42.

28. Wyrwich KW, Krishnan S, Auguste P, et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: Results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016;22:866-872.

29. Su J, Tsao E, Feng J, Myren K, Glazebrook D. Long-term quality-of-life outcomes with rFVIII:Fc prophylaxis in adult subjects with severe haemophilia A. Res Practice Thromb Haemostasis. 2018;1(Suppl 1):788.

30. Knobe K, Berntorp E. Haemophilia and joint disease: Pathophysiology, evaluation, and management. J Comorbid. 2011;1:51-59.

31. Lobet S, Herman C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med. 2014;5:207-218.

32. Oldenburg J, Pasi KJ, Pabinger I, Nolan B, Kulkarni R, Blanchette V, Tripkovic N, Feng J, Jain N. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. European Association of Haemophilia and Allied Disorders (EAHAD) 12th annual congress 2019; Poster: P158.

33. Oldenburg J, Kulkarni R, Srivastava A, et al. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018;24:77-84.

34. Chowdary P, Ragni M, Pabinger I, Feng J, Lethagen S, Barnowski C, Mahlangu J. Recombinant factor VIII Fc fusion protein (rFVIII:Fc) efficacy for perioperative haemostatic management in severe haemophilia A. World Federation of Haemophilia (WFH) 16th International Musculoskeletal Congress 2019; Poster: P-14.

35. Taki M, Fukutake K, Kobayashi M, Nagao A, Makioka H, Shiraishi M. Initial safety results from a prospective post-marketing surveillance study using rFVIII:Fc in the real world setting in Japanese hemophilia A patients. Res Practice Thromb Haemostasis. 2017;1(Suppl 1):738.

36. Saad S, Altay C, Ahmed P, Zafar L, Iqbal M, Zafar T. Clinical efficacy of recombinant factor VIII Fc fusion protein in hemophilia A patient receiving on demand treatment only, a cross sectional study. Haemophilia. 2018;24(Suppl 5):S58.

37. Tagliaferri A, Matichecchia A, Rivolta GF, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII:Fc: a single-centre real-world experience. Blood Transfus. 2020;18:374-385.

38. Jimenez R, Nuñez R, Jimenez P, Rodriguez-Martorell F, Perez-Simon J. Switch to extended half-life recombinant factor VIII Fc in severe hemophilia A patients under prophylaxis. Experience in one centre. Haemophilia. 2018;24(Suppl 1):117.

39. Apte S, Subramanian K, Swami M, et al. Low dose (20 IU/kg/week), single infusion prophylaxis using long acting FVIIIc (Eloctate) in severe haemophilia A. Haemophilia. 2018;24(Suppl 5):93.

40. Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia. 2018;24:414-419.

41. Ruiz-Saez A, Boadas A, Echenagucia M. Use of extended half-life rFVIII-Fc or rFIX-Fc in previously treated patients with hemophilia A or B. A single center experience. Haemophilia. 2019;25(Suppl 1):S00-S01.

42. García MF, Fernandez Caballer M, Juarez Gimenez JC, et al. Clinical impact and pharmacoeconomic analysis of efmoroctocog alfa treatment in patients with severe hemophilia A. Haemophilia. 2019;25(Suppl 1):130.

43. Pevyandi F, Garagiola I, Boscarno M, Ryan A, Hermans C, Makris M. Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia. 2019;25:946-952.

44. Scott M, Wall C, Xiang H, et al. A within-patient and matched-pair comparison of real-world outcomes in patients using rFVIII and rFIX:Fc prophylaxis, in the UK. Haemophilia. 2020;26(Suppl 2):63.

45. Delmotte N, Roche M, Giraud R, et al. Recombinant factor VIII Fc (rFVIIIFc) in real life: Clinical and economic outcomes. Haemophilia. 2019;25(Suppl 1):103.

46. Ebbert P, Ragni M, Xavier F, Malec L, Seaman C. Observational study of recombinant factor-VIII-Fc, Eloctate, in hemophilia patients with and without inhibitors. Blood. 2017;130:3689.

47. Komitopoulou A, Pergantou H, Mazarakis M, et al. Use of extended half-life factor VIII products in children with severe hemophilia A on prophylaxis: A single centre experience. Haemophilia. 2018;24(Suppl 1):54.

48. Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S. Association of hemophilia centre directors of Canada. Switching to extended half-life products in Canada - preliminary data. Haemophilia. 2017;23:e365-e367.

49. Oldenburg J, Heller C, Malmström H, Winding S, Lethagen S. No relapse in patients with previous inhibitors switched to rFVIII:Fc in ongoing observational Phase 4 studies. Res Pract Thromb Haemost. 2020;4(Suppl 1):463-464.

50. Dubé E, Bonnefoy A, Merlen C, et al. A prospective surveillance study of inhibitor development in hemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII. Haemophilia. 2018;24:236-244.

51. Abraham A, Srivastava A. Surgical prophylaxis using long acting factor concentrate in a cohort of hemophilia patients. Haemophilia. 2018;24(Suppl 5):20-21.

52. Apte S, Phatale R, Joshi A. Bilateral, simultaneous total knee replacement (TKR) surgery for hemophilia A with Eloctate (extended half life product) - a feasible and cost effective approach. Blood. 2018;132:4684.

53. Hellal M, Alvi A, Tait R. Experience of major orthopaedic surgery in severe haemophilia A with extended half-life factor FVIII Fc fusion protein. World Federation of Haemophilia (WFH). World Congress. 2018;13:85.

54. Kremer H, Schutgens R, Van Vulpen L, Mauser-Bunschoten E, Fischer K. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Haemophilia. 2018;24:e280-e283.

55. Lienhart A, Meunier S, Nougier C. Which FVIII: C assay for the monitoring of patients with hemophilia undergoing surgery under the cover of FVIII:Fc fusion protein? European Congress on. Thromb Haemost. 2018;28:129.

56. Okamoto A, Yamamoto K, Eguchi G, et al. Perioperative management of haemophilia A using recombinant factor VIII Fc fusion protein in a patient undergoing endoscopic nasal pituitary adenomectomy for a growth hormone-producing pituitary adenoma. Haemophilia. 2017;23:e525-e527.

57. Fujii T, Yamasaki N, Fujii T. Extended half-life factor VIII management of hemophilia A undergoing surgery is not only efficient but also contributes to saving the factor consumption compared to standard half-life products. Res Pract Thromb Haemost. 2019;3(Suppl 1):269.
58. Winding B, Oldenberg J, Peyvandi F, et al. Rationale and study design for a prospective, non-interventional phase 4 study evaluating the effectiveness of recombinant factor VIII Fc compared with conventional factor VIII concentrates in the prophylactic treatment of haemophilia A: The A-SURE study. Res Pract Thromb Haemost. 2017;1(5):678-679.

59. Königs C, Ozelo MC, Dunn A, et al. Final results of PUPs A-LONG study: evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A. Res Pract Thromb Haemost. 2020;4(Suppl 1):8. (abstract OC 03.02).

60. Gouw SC, van der Bom JG, Ljung R, et al. van den Berg HM, PedNet & Rodin Study Group. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med. 2016;376:2054-2064.

61. Peyvandi F, Mannucci P, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in haemophilia A. N Engl J Med. 2016;374:2054-2064.

62. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A: The CANAL cohort study. Blood. 2007;109:4693-4697.

63. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999;5:145-154.

64. Blumberg RS, Lillicrap D. IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. 2018;131:2205-2214.

65. Krishnamoorthy S, Liu T, Drager D, et al. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol. 2016;301:30-39.

66. Liu T, Hoehn T, Patarroyo-White S, Pierce G, Jiang H. Evaluation of antibody responses to rFVIIIFc compared to Xyntha and Advate in hemophilia A mice. Haemophilia. 2012;18(Suppl 3):41.

67. Janbain M, Pipe S. What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors? Hematol Res Pract Thromb HBO 2018: Poster P 059.

68. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide ‘Tregitopes’. Blood. 2008;112:3303-3311.

69. Groomes CL, Gianferante DM, Crouch GD, Parekh DS, Scott DW, Lieuw K. Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-Fc fusion protein. Pediatr Blood Cancer. 2016;63:922-924.

70. Malec LM, Journeycake J, Ragni MV. Extended half-life factor VIII for immune tolerance induction in haemophilia. Haemophilia. 2016;22:e552-e554.

71. Abraham A, Apte S, Shamukhaiah C, et al. Outcome of immune tolerance induction using an extended half-life clotting factor concentrate - recombinant factor VIII Fc (Eloctate™) - a report from India. Blood. 2018;132:2494.

72. Carcao M, Shapiro A, Staber JM, et al. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors - a retrospective analysis. Haemophilia. 2018;24:245-252.

73. Carcao M, Shapiro A, Hwang N, et al. Real-world data of immune tolerance induction (ITI) using recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A with inhibitors at high risk for ITI failure. Hemostasis and Thrombosis Research Society (HTRS)/North American Society on Thrombosis and Hemostasis (NASTH) Scientific Symposium 2019: Poster 12.

74. Malec LM, Carcao M, Jain N, et al. rFVIIIFc for first-time immune tolerance induction (ITI) therapy: Interim results from the global, prospective vertITI-8 study. Res Pract Thromb Haemost. 2019;3(5):97-98.

75. Sobi. The Republic of Ireland switches all people with haemophilia A & B treated with replacement clotting factors to Sobi. s™ extended half-life therapies. 2018. Available at: https://www.Sobi.com/en/investors/republic-ireland-switches-all-people-haemophilia-b-treated-replacement-clotting-factors.

76. Tiede A. Design of a prospective, non-interventional study evaluating real-world usage and effectiveness of Elocta (rFVIIIFc) and Alprolix (rFIXFc) in the prophylactic treatment of haemophilia A and B: The PREVENT study. 62nd Annual Meeting of the Society of Thrombosis and Haemostasis Research Society (GTH) 2018: Poster P 059.

77. Pierce GF, Haffar A, Ampartzidis G, et al. First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia. 2018:24:229-235.

78. Seth Chhabra E, Liu T, Kulman J, et al. Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent. Blood. 2020;135:1484-1496.

79. Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020:383:1018-1027.

How to cite this article: Hermans C, Mancuso ME, Nolan B, Pasi KJ. Recombinant factor VIII Fc for the treatment of haemophilia A. Eur J Haematol. 2021;106:745–761. https://doi.org/10.1111/ejh.13610